Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 09:00 ET | Source: Imunon, Inc.

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...
November 07, 2022 08:30 ET | Source: Imunon, Inc.

Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022

LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines,...
November 11, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
September 27, 2018 09:00 ET | Source: ConSynance Therapeutics, Inc.

ConSynance Presents CSTI-100 Data at NASH Conference

Rensselaer, New York., Sept. 27, 2018 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. announced today that Peter Guzzo, Ph.D., CEO, gave an oral presentation regarding the company's Phase I...